EYEN Eyenovia Inc

Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference

Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer and John Gandolfo, Eyenovia’s Chief Financial Officer, are scheduled to present at the 22nd Annual H.C. Wainwright Global Investment Conference being held virtually on September 14-16, 2020.

Details of the presentation are below:

Event: 22nd Annual H.C. Wainwright Global Investment Conference

Date: Tuesday, September 15, 2020

Presentation Time: 2:30-2:50 PM ET

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, please visit .

Company Contact:

Eyenovia, Inc.

John Gandolfo

Chief Financial Officer

Investor Contact:

The Ruth Group

Carol Ruth

Phone: 646-536-7004

 

EN
09/09/2020

Underlying

EYENEyenovia Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eyenovia Inc

 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Announces Co-Branded Validator with Kinetiq 

Eyenovia Announces Co-Branded Validator with Kinetiq  Kinetiq x Hyperion provides a premier liquid staking solution for institutional HYPE holders LAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced a co-branded Hyperliquid validator with Kinetiq, a leading liquid staking protocol built natively for the Hyperliquid ecosystem.  The validator mar...

June 25, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Announces Closing of $50 Million Private Placement, Successfu...

Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program The significant HYPE token position, acquired at an average price of approximately $34 per token, makes Eyenovia the first Nasdaq listed company to run a validator on Hyperliquid FDA registration of the Optejet User Filled Device (UFD) on track for September 2025; meaningful partnering discussions ongoing LAGUNA HILLS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Com...

June 23, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Announces Appointment of a Strategic Advisor for Digital Asse...

Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced several key developments in support of its digital asset capita...

June 18, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYP...

Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy Announces private placement EYEN to become first U.S.-based publicly listed company to hold HYPE in its treasury Hyunsu Jung appointed Chief Investment Officer and Board Member LAGUNA HILLS, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”) today announced that it has entered into a securities purchase agreement (the “SPA”) for a $50 million private placement in public equity (the “PIPE Financing”) with institutional...

June 17, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Provides Updates on Potential Merger with Betaliq and Develop...

Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the user-filled Optejet, and remains on track to file for U.S. device regulatory approval in September 2025 Reduced ongoing cash burn by approximately 70% versus prior year and improved debt repayment terms LAGUNA HILLS, Calif....

May 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch